Department of Health and Human Services Awarded a Contract to AALIS MANAGEMENT CONSULTING LLC for $4,500,000.00

Summary of Award

In a substantial contract awarded by the U.S. federal government, the Food and Drug Administration (FDA), a part of the Department of Health and Human Services (HHS), entered into an agreement with AALIS Management Consulting LLC. This contract, identified with the unique award ID "CONT_IDV_75F40122D00030_7524," is an Indefinite Delivery/Indefinite Quantity (IDV) contract, which allows the government to procure an indefinite quantity of services during a fixed period. The contract was signed on September 28, 2022, and is set to run until September 28, 2024.

The primary purpose of this contractual arrangement is to secure budget consultant support services for the FDA’s Center for Biologics Evaluation and Research (CBER), particularly within the Office of Management. The total potential value of the contract, inclusive of all options, is $4.5 million. The nature of the IDV contract suggests it will accommodate various orders as required, though specific transactions concerning obligations or outlays have yet to be initiated, according to the data.

A notable aspect of this award is its classification as an 8(a) Sole Source contract. This designation indicates that the award was made under the Small Business Administration’s 8(a) Business Development Program, which supports minority-owned businesses. AALIS Management Consulting fits this profile, highlighting its status as a minority-owned and economically disadvantaged women-owned small business. The company is also a service-disabled veteran-owned business, adding layers of diversity underrepresented in federal contracting. AALIS Management Consulting LLC, based in Woodbridge, Virginia, specializes in administrative management and general management consulting services, categorized under NAICS code 541611. This underscores its expertise in providing professional, administrative, and management solutions, aligning with the contract's requirements for budget consultancy. The firm’s capability to cater to the FDA’s financial management needs speaks to its proficiency in these services and its strategic positioning to handle extensive government projects. The contract's solicitation process was exclusive, receiving only one offer. This limited competitive nature underscores the unique qualifications and set-aside programs that determined AALIS Management Consulting as the optimal candidate. The use of solicitation procedures marked as “SSS,” or Sole Source Selection, reaffirms the strategic selection under the 8(a) program. The extent of competition was noted as “not available for competition,” indicating reliance on statutory provisions to award this contract without full competition, guided by FAR 6.302-5(a)(2)(i). The classification codes associated with the contract—specifically, PSC code "R499" and NAICS code "541611"—pinpoint the precise nature of services AALIS Management Consulting is expected to deliver. These services fall under broad categories of professional and technical consulting, with an emphasis on administration, making the company a fitting partner for the FDA’s needs. Funding and oversight of this contract are managed by the FDA’s Office of Acquisition and Grant Services, ensuring alignment with departmental goals and regulations. While the contract is active, as of the last update in December 2022, there remain no sub-awards or financial transactions recorded against the contract, indicating that work might still be in preliminary phases. The recipient's business status in diverse categories such as U.S.-owned business, veteran-owned, and women-owned speaks to a robust representation of various American small business sectors. This diversity highlights federal efforts to engage and empower traditionally underrepresented groups through significant contracts and economic opportunities. In sum, the awarded contract to AALIS Management Consulting LLC showcases a strategic match of expertise and capability in budget consultancy with specific federal support mechanisms like the 8(a) program. It speaks to a broader ambition to integrate small, minority-, and woman-owned businesses into the federal contracting eco-system, aligning economic empowerment with essential governmental tasks aimed at efficient financial management within critical agencies such as the FDA. As this obligation unfolds, it remains poised to contribute meaningfully to the operations of the FDA’s Center for Biologics Evaluation and Research, ensuring thorough stewardship of federal health initiatives.